Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_205_библиотеки_им_акад_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
13 Мб
Скачать
☆
292 The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
cant differences were found between the two agents in symptomatic mania remission and relapse rates. Tolerability was generally better for divalproex than for olanzapine.
Asenapine: A Sublingual Antipsychotic
The development of asenapine (trade name Saphris) was almost derailed by its poor bioavailability and extensive hepatic-gastrointestinal metabolism. Thus, it became the first sublingual SGA and is absorbed via the oral mucosa. On the basis of success ful controlled clinical trials, asenapine received FDA approval for both schizophrenia and mania, but not for depression. It is an antagonist at D addition, it exhibits a high affinity for multiple serotonin, dopamine, α-adrenergic, and histamine receptors. The peak plasma concentration is 30–90 minutes, and the half-life is 24 hours (Citrome 2014). When used for bipolar maintenance, asenapine monotherapy was found to be superior to placebo in delaying relapse to manic and depressive episodes (NNT=5). Side effects include somnolence, akathisia, and seda tion (Szegedi et al. 2018). Patients receiving asenapine experienced greater symptom remission of acute mania (NNT=22) in comparison with placebo-treated patients, but not in comparison with olanzapine-treated patients (NNT=12) (McIntyre et al. 2010).
and 5-HT2A receptors. In
2
Role of Long-Acting Injectables in Mood Disorder Treatment
-
-
Long-Acting Risperidone
Quiroz et al. (2010) performed the largest published randomized controlled trial to date studying the effectiveness of injectable long-acting risperidone (LAR) as mainte nance monotherapy for bipolar disorder. Patients with a history of more manic epi­sodes than depressed episodes who were either currently stable or in a manic or mixed state were randomly assigned to continue the same dosage of LAR or to switch to pla cebo. They were then followed for 26 weeks, with a primary endpoint of time to re­lapse to any mood episode (depressive, manic, hypomanic, or mixed). Among patients assigned to receive LAR, 29% relapsed, compared with 57% of patients assigned to re ceive placebo. LAR therapy was superior to placebo in delaying time to relapse to any mood episode, regardless of whether patients were acutely manic or stable on risper idone, other antipsychotics, or mood stabilizers at enrollment.
Aripiprazole Once-Monthly Injections
The efficacy of oral aripiprazole in bipolar I disorder as both monotherapy and adjunc­tive therapy in both acute and maintenance treatment of bipolar mania has already been established in randomized controlled studies, and it has received FDA approval for the treatment of manic or mixed episodes associated with bipolar I disorder. Re­search on the use of long-acting injectables in the treatment of bipolar I disorder is lim­ited. Some studies have examined the effectiveness of aripiprazole once-monthly 400­mg (AOM 400) injections in the treatment of bipolar I disorder in the maintenance phase. In a double-blind, randomized, placebo-controlled, multicenter withdrawal study, patients (N=133) were transitioned to and stabilized on oral aripiprazole mono­therapy and then transitioned to AOM 400 injections every 4 weeks (Calabrese et al.
2017). After 8 weeks on AOM 400, patients who met stability criteria were randomly assigned (in a one-to-one ratio) to the maintenance phase, consisting of 52 weeks of
-
-
-
-
293 Role of Antipsychotics in Mood Disorder Treatment
https://t.me/med1917
double-blind treatment with either AOM 400 or placebo. The primary efficacy end­point was time from randomization to recurrence of any mood episode. After 1 year, the time to recurrence of any mood episode was reduced by approximately one-half among patients receiving AOM 400 compared with those receiving placebo; 26.5% of patients in the AOM 400 group experienced a mood episode recurrence, compared with 51.1% of patients in the placebo group.
Pimavanserin: Beyond Parkinson’s Disease
Pimavanserin is a newer antipsychotic that was approved for the treatment of hallu­cinations and delusions associated with Parkinson’s disease psychosis due to its unique absence of any dopamine blockade and its action as an inverse agonist at the 5-HT motor symptoms of Parkinson’s disease like dopamine antagonists do. Clinical trials examining the effectiveness of pimavanserin as an adjunctive therapy for treatment­resistant MDD are currently under way. Recently, Acadia Pharmaceuticals (2019) completed the Phase II CLARITY study, a 10-week randomized, double-blind, pla­cebo-controlled multicenter study that evaluated the efficacy, safety, and tolerability of pimavanserin administered as an adjunctive treatment to patients with MDD who had an inadequate response to an SSRI or a serotonin-norepinephrine reuptake inhib itor (SNRI). The researchers found significant reductions in scores on the 17-item Hamilton Depression Rating Scale (the primary outcome measure) among patients given pimavanserin compared with those given placebo. These encouraging results led to initiation of the Phase III CLARITY program to continue to evaluate pimavan­serin as an adjunctive therapy for patients who are already taking a stable dosage of an SSRI or SNRI but are having an inadequate response (Fava et al. 2019).
and 5-HT2C receptors (Acadia Pharmaceuticals 2016). It does not worsen the
2A
-
Conclusion
Antipsychotic medications, both first- and second-generation agents, have been widely used for mood disorders, sometimes off-label but more recently (with SGAs) for FDA-approved indications based on findings from controlled clinical trials. Anti­psychotics have been demonstrated to be quite useful for unipolar depression (MDD) both as monotherapy and in combination with antidepressants, especially for pa­tients with treatment-resistant illness. On the other hand, bipolar depression, which for decades has been treated with the traditional antidepressants approved for unipo­lar depression (MDD), now has three SGA medications approved by the FDA (quetia­pine in 2005, lurasidone in 2013, and cariprazine in 2019) for use either as monotherapy or as an adjunct to treatment with a mood stabilizer (lithium or valproate). The manic phase of bipolar disorder has been successfully treated since the 1950s with the FGAs and since 2003 with various SGAs. The exact mechanisms by which antipsychotic drugs exert their antidepressant effects remain unknown, but recent reports of the antidepressant efficacy of the first nondopaminergic antipsychotic drug, pimavanse­rin, which is an inverse agonist of serotonin 5-HT nism of the SGAs (in addition to their dopamine antagonism) may play a role in their
, suggest that the 5-HT2A antago-
2A
294 The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
antidepressant effects. Further research into the role of antipsychotic drugs in treating mood disorders is warranted.
References
Acadia Pharmaceuticals: Nuplazid [package insert]. San Diego, CA, Acadia Pharmaceuticals,
Inc, 2016
Acadia Pharmaceuticals: Acadia Pharmaceuticals to present phase 2 CLARITY results for pima-
vanserin as an adjunctive treatment in major depressive disorder at the 2019 American Psy­chiatric Association Annual Meeting. BioSpace, May 18, 2019. Available at: https:// www.biospace.com/article/releases/acadia-pharmaceuticals-to-present-phase-2-clarity­results-for-pimavanserin-as-an-adjunctive-treatment-in-major-depressive-disorder-at-the­2019-american-psychiatric-association-annual-meeting/. Accessed July 27, 2019.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 2nd
Edition. Washington, DC, American Psychiatric Association, 1968
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd
Edition. Washington, DC, American Psychiatric Association, 1980
Angst J, Marneros A: Bipolarity from ancient to modern times: conception, birth and rebirth.
J Affect Disord 67(1–3):3–19, 2001 11869749
Ban TA: Amoxapine and viloxazine: review of the literature with special reference to clinical
studies. Psychopharmacol Bull 15(3):22–25, 1979 386404
Bawa R, Scarff JR: Lurasidone: a new treatment option for bipolar depression—a review. Innov
Clin Neurosci 12(1–2):21–23, 2015 25852975
Bowden CL, Grunze H, Mullen J, et al: A randomized, double-blind, placebo-controlled effi-
cacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disor­der. J Clin Psychiatry 66(1):111–121, 2005 15669897
Burris KD, Molski TF, Xu C, et al: Aripiprazole, a novel antipsychotic, is a high-affinity partial
agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302(1):381–389, 2002 12065741
Calabrese JR, Sanchez R, Jin N, et al: Efficacy and safety of aripiprazole once-monthly in the
maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry 78(3):324–331, 2017 28146613
Caley CF, Cooper CK: Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother
36(5):839–851, 2002 11978164
Camm AJ, Karayal ON, Meltzer H, et al: Ziprasidone and the corrected QT interval: a compre-
hensive summary of clinical data. CNS Drugs 26(4):351–365, 2012 22452529
Cipriani A, Rendell JM, Geddes JR: Haloperidol alone or in combination for acute mania. Co-
chrane Database Syst Rev (3):CD004362, 2006 16856043
Citrome L: Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and
metabolism. Expert Opin Drug Metab Toxicol 10(6):893–903, 2014 24793403
Cuellar AK, Johnson SL, Winters R: Distinctions between bipolar and unipolar depression. Clin
Psychol Rev 25(3):307–339, 2005 15792852
Dorfman W: The use of protriptyline (MK-240) as an antidepressant; a preliminary report. Am
J Psychiatry 120(6):594–595, 1963 14086441
Durgam S, Earley W, Guo H, et al: Efficacy and safety of adjunctive cariprazine in inadequate re-
sponders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry 77(3):371–378, 2016a 27046309
Durgam S, Earley W, Lipschitz A, et al: An 8-week randomized, double-blind, placebo-controlled
evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry 173(3):271–281, 2016b 26541814
Fava M, Dirks B, Freeman MP, et al: A phase 2, randomized, double-blind, placebo-controlled
study of adjunctive pimavanserin in patients with major depressive disorder and an inad­equate response to therapy (CLARITY). J Clin Psychiatry 80(6):19m12928, 2019 31556975
295 Role of Antipsychotics in Mood Disorder Treatment
https://t.me/med1917
Gebara MA, DiNapoli EA, Kasckow J, et al: Specific depressive symptoms predict remission to
aripiprazole augmentation in late-life treatment resistant depression. Int J Geriatr Psychi atry 33(2):e330–e335, 2018 28975710
Keck PE Jr, Calabrese JR, McIntyre RS, et al: Aripiprazole monotherapy for maintenance ther-
apy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68(10):1480–1491, 2007 17960961
Kennedy RE, Miller JJ: Amitriptyline-perphenazine in the treatment of schizophrenia. Am J
Psychiatry 119(11):1092–1093, 1963 14031956
Keshavan MS, Lawler AN, Nasrallah HA, et al: New drug developments in psychosis: chal-
lenges, opportunities and strategies. Prog Neurobiol 152:3–20, 2017 27519538
Kinghorn WA, McEvoy JP: Aripiprazole: pharmacology, efficacy, safety and tolerability. Expert
Rev Neurother 5(3):297–307, 2005 15938662
Lenze EJ, Mulsant BH, Blumberger DM, et al: Efficacy, safety, and tolerability of augmentation
pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a ran domised, double-blind, placebo-controlled trial. Lancet 386(10011):2404–2412, 2015 26423182
Lindström L, Lindström E, Nilsson M, et al: Maintenance therapy with second generation anti-
psychotics for bipolar disorder—a systematic review and meta-analysis. J Affect Disord 213:138–150, 2017 28222360
Loebel A, Cucchiaro J, Silva R, et al: Lurasidone monotherapy in the treatment of bipolar I de-
pression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 171(2):160–168, 2014 24170180
Lydiard RB, Gelenberg AJ: Amoxapine—an antidepressant with some neuroleptic properties?
A review of its chemistry, animal pharmacology and toxicology, human pharmacology, and clinical efficacy. Pharmacotherapy 1(3):163–178, 1981 6152816
Lyons DJ, Ammari R, Hellysaz A, et al: Serotonin and antidepressant SSRIs inhibit rat neuro-
endocrine dopamine neurons: parallel actions in the lactotrophic axis. J Neurosci 36(28):7392–7406, 2016 27413150
Mandrioli R, Protti M, Mercolini L: Evaluation of the pharmacokinetics, safety and clinical effi-
cacy of ziprasidone for the treatment of schizophrenia and bipolar disorder. Expert Opin Drug Metab Toxicol 11(1):149–174, 2015 25483358
Marcus R, Khan A, Rollin L, et al: Efficacy of aripiprazole adjunctive to lithium or valproate in
the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipo lar Disord 13(2):133–144, 2011 21443567
McIntyre RS, Cohen M, Zhao J, et al: Asenapine in the treatment of acute mania in bipolar I dis-
order: a randomized, double-blind, placebo-controlled trial. J Affect Disord 122(1–2):27– 38, 2010 20096936
McIntyre RS, Cha DS, Kim RD, et al: A review of FDA-approved treatment options in bipolar
depression. CNS Spectr 18 (suppl 1):4–20, quiz 21, 2013 24237641
Nasrallah HA, Tandon R: Classic antipsychotic medications, in Essentials of Clinical Psycho-
pharmacology, 4th Edition. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Publishing, 2017, pp 603–621
Nemeroff CB, Kinkead B, Goldstein J: Quetiapine: preclinical studies, pharmacokinetics, drug
interactions, and dosing. J Clin Psychiatry 63 (suppl 13):5–11, 2002 12562141
Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a compre-
hensive literature review. CNS Drugs 19 (1 suppl 1):1–93, 2005 15998156
Otsuka American Pharmaceutical: Abilify prescribing information. June 2020. Available at:
https://www.otsuka-us.com/sites/g/files/qhldwo3916/files/media/static/Abilify­M-PI.pdf. Accessed November 17, 2020.
Papakostas GI, Petersen TJ, Kinrys G, et al: Aripiprazole augmentation of selective serotonin
reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 66(10):1326–1330, 2005 16259548
Papakostas GI, Fava M, Freeman MP, et al: Effect of pimavanserin on anxious depression in pa-
tients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. Int Clin Psychopharmacol 35(6):313–321, 2020 32804742
-
-
-
296 The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
Park YW, Kim Y, Lee JH: Antipsychotic-induced sexual dysfunction and its management.
World J Mens Health 30(3):153–159, 2012 23596605
Patkar AA, Pae CU, Vöhringer PA, et al: A 13-week, randomized double-blind, placebo-
controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. J Clin Psychophar macol 35(3):319–323, 2015 25882763
Quiroz JA, Yatham LN, Palumbo JM, et al: Risperidone long-acting injectable monotherapy in the
maintenance treatment of bipolar I disorder. Biol Psychiatry 68(2):156–162, 2010 20227682
Rosen RC, Lane RM, Menza M: Effects of SSRIs on sexual function: a critical review. J Clin Psy-
chopharmacol 19(1):67–85, 1999 9934946
Sachs GS, Vanderburg DG, Karayal ON, et al: Adjunctive oral ziprasidone in patients with
acute mania treated with lithium or divalproex, part 1: results of a randomized, double­blind, placebo-controlled trial. J Clin Psychiatry 73(11):1412–1419, 2012 23218157
Shelton RC: The combination of olanzapine and fluoxetine in mood disorders. Expert Opin
Pharmacother 4(7):1175–1183, 2003 12831342
Shelton RC: The return of fixed combinations in psychiatry: fluoxetine and olanzapine combi-
nation. Ther Clin Risk Manag 2(2):187–192, 2006 18360592
Shelton RC, Tollefson GD, Tohen M, et al: A novel augmentation strategy for treating resistant
major depression. Am J Psychiatry 158(1):131–134, 2001 11136647
Smith ME: Perphenazine and amitriptyline as adjuncts to psychotherapy. Am J Psychiatry
120(1):76–77, 1963 13989519
Smith e Incas J: Combined amitriptyline and perphenazine (Etrafon) in the treatment of severe
emotional disorders. J Natl Med Assoc 57(4):284–286, 1965 5864895
Spiker DG, Weiss JC, Dealy RS, et al: The pharmacological treatment of delusional depression.
Am J Psychiatry 142(4):430–436, 1985 3883815
Szegedi A, Durgam S, Mackle M, et al: Randomized, double-blind, placebo-controlled trial of
asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry 175(1):71–79, 2018 28946761
Thase ME, Youakim JM, Skuban A, et al: Efficacy and safety of adjunctive brexpiprazole 2 mg in
major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 76(9):1224–1231, 2015 26301701
Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al: A 12-week, double-blind compari-
son of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 60(12):1218–1226, 2003a 14662554
Tohen M, Ketter TA, Zarate CA, et al: Olanzapine versus divalproex sodium for the treatment
of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 160(7):1263–1271, 2003b 12832240
Trede K, Salvatore P, Baethge C, et al: Manic-depressive illness: evolution in Kraepelin’s Text-
book, 1883–1926. Harv Rev Psychiatry 13(3):155–178, 2005 16020028
Vieta E, Sanchez-Moreno J: Acute and long-term treatment of mania. Dialogues Clin Neurosci
10(2):165–179, 2008 18689287
Weisler RH, Nolen WA, Neijber A, et al: Continuation of quetiapine versus switching to pla-
cebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 72(11):1452–1464, 2011 22054050
Zhou FM, Liang Y, Salas R, et al: Corelease of dopamine and serotonin from striatal dopamine
terminals. Neuron 46(1):65–74, 2005 15820694
-
CHAPTER 18
https://t.me/med1917
Electroconvulsive Therapy
William McDonald, M.D.
Electroconvulsive therapy (ECT) has been referred to as the “gold
standard” in the treatment of mood disorders (Kellner et al. 2012). ECT is the penul timate treatment in algorithmic strategies for patients whose depression is most re­sistant (Conway et al. 2017; Thase and Rush 1997), and failure to respond to a course of ECT is considered as confirmation that a patient has treatment-resistant depression (TRD) (Fink 2001). However, some have argued that ECT should be used earlier in the TRD algorithm, given the negative effects of chronic depression on quality of life, morbidity, and mortality, associated specifically with completed suicide (Beale and Kellner 2000). A study of the cost-effectiveness of ECT found that it significantly reduced patient time in depression, especially when offered early in the treatment course (Ross et al. 2018). The economic advantages were most apparent when ECT was initiated after only two antidepressant failures, in line with a widely accepted algorithm for when to consider ECT (Conway et al. 2017).
Psychotherapy and pharmacological trials may take weeks or months to be effec­tive in TRD. In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial funded by the National Institute of Mental Health, researchers tested an evi dence-based treatment algorithm and found that after two unsuccessful trials of anti­depressant medication, the patient’s chance of remission was as low as 15%, and the rate of relapse if they did respond was as high as 65% (Rush et al. 2019). Patients in populations with treatment-resistant illness who are administered ECT generally have remission rates of 60%–80% (O’Connor et al. 2001), with a relapse rate of less than 50% when they are maintained on a standardized maintenance pharmacotherapy regimen in the 6 months following a successful acute course of ECT (Sackeim et al. 2001). Fur­thermore, ECT has been shown to be effective in rapidly decreasing suicidal ideation (Kellner et al. 2005), with remission rates as high as 95% in patients with psychotic de­pression (Petrides et al. 2001).
Despite the clinical efficacy of ECT, the rate of U.S. hospitals providing it actually decreased significantly in the period from 1993 to 2009, dropping from 14.8% to 10.6%
-
-
297
298 The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
(Case et al. 2013). A meta-analysis of 18 studies from 12 countries suggested a decline in the use of ECT in the period from 1973 to 2013, with significant variation among countries (Lesage et al. 2016). Some countries including China and The Netherlands have seen a rise in the use of ECT, whereas Canada (Rapoport et al. 2006) and Den­mark (Munk-Olsen et al. 2006) have seen use remain stable. South London, England (Lambe et al. 2014), and Sydney, Australia (Plakiotis et al. 2012), have seen a decline.
Several potential reasons for the discrepancy in the efficacy and utilization of ECT, which are interrelated, include the availability of the treatment, the stigma associated with ECT, and concerns regarding side effects. The rates of use are directly related to the availability of the treatment and number of psychiatrists in the community and are indirectly related to state regulations restricting the use of ECT (Hermann et al.
1995). The availability of the treatment in the community is a product of both the at titudes of providers and patients toward the treatment and its associated costs.
There is no doubt that ECT has been unfairly stigmatized in the media and on the internet (Griffiths and O’Neill-Kerr 2019; Matthews et al. 2016; Sienaert 2016). Con sider the impact of One Flew Over the Cuckoo’s Nest on the perception of ECT (Hilton
2007). Researchers have found an indirect relationship between stigmatizing atti tudes toward ECT and individuals’ personal and factual knowledge related to the treatment (Kring et al. 2018). Patient family members (Elias et al. 2019), psychologists, nurses, social workers (Janicak et al. 1985), and medical students (Trenton and Pelchat
2016) reported a more positive view of ECT that was directly related to their familiar­ity with the procedure. Whether ECT is recommended is also related to the psychia­trist’s view of the procedure (Latey and Fahy 1985). Providing full informed consent to patients and education to families and caregivers can mitigate unfounded concerns about the procedure and allow patients to make an informed decision regarding their treatment (Sackeim et al. 1995).
The costs associated with ECT can also be a barrier to its availability. ECT is in­creasingly being administered in treatment settings with anesthesia providers and advanced medical equipment monitoring the patient during and after the treatment. As a result, ECT is one of the safest procedures performed under general anesthesia, with a mortality rate of 1 death in 73,440 in a Veterans Affairs study (0.001%) (Watts et al. 2011) and 0.002% in a study that included 32 countries with 766,180 total treat ments (Tørring et al. 2017). The increased costs associated with these medical advances may be a barrier for some patients, although the overall cost savings of ECT and im­provement in areas such as patient quality of life are clear (Giacobbe et al. 2018; McCall et al. 2006; McDonald et al. 1998; Ross et al. 2018; Steffens et al. 1995).
Given the advantages of ECT in treating the most refractory mood disorders, ECT research has been focused on improving its safety while maintaining its efficacy. This research has resulted in several important modifications in the administration of ECT, including identifying patient characteristics associated with response to ECT, person­alizing the treatment parameters based on the identified seizure threshold, using alter­native electrode placements, and employing strategies to prevent or minimize relapse.
This review focuses on the evidence for identifying the “ideal patient” for ECT and on maximizing the efficacy of ECT in the treatment of mood disorders. A number of neuromodulation treatments can also be effective in TRD (e.g., repetitive transcranial magnetic stimulation [rTMS], transcranial direct current stimulation [tDCS], vagal nerve stimulation [VNS], deep brain stimulation [DBS]); data are limited on which
-
-
-
-
299 Electroconvulsive Therapy
https://t.me/med1917
treatment would be most appropriate for the individual patient. Understanding where ECT fits in the treatment of patients with mood disorders can help personalize treatment.
Identifying Patients Most Likely to Benefit
Clinical Markers of Response
An algorithm that determines which patients should be considered for ECT should weigh the relative risks and benefits of ECT compared with those of alternative treat ments for major depressive disorder. Should the patient receive another course of antidepressants, a trial of rTMS, off-label ketamine infusions or nasal esketamine in sufflation therapy, VNS, or investigational treatments such as DBS? In fact, relatively few data comparing the efficacy of these treatments are available. ECT is often used to provide evidence of treatment resistance (e.g., early investigational trials of VNS and DBS), or alternative treatments are used instead of ECT in patients concerned about the cognitive side effects of the treatment (e.g., esketamine and rTMS). Under standing the ideal patient for this treatment based on the patient’s clinical character­istics is an important role of the practitioner prescribing a course of ECT to an indi­vidual patient for TRD.
When determining which patients are most appropriate for ECT, several patient clinical characteristics associated with an acute response to ECT should be consid ered. Response to ECT has been associated with increased age and a diagnosis of psy­chotic depression (Dombrovski et al. 2005; Haq et al. 2015; van Diermen et al. 2018). Additional predictors of response include psychomotor retardation and increased de pression severity (Haq et al. 2015; Heijnen et al. 2019; van Diermen et al. 2018). Neg­ative predictors include a diagnosis of comorbid personality disorder (specifically
creased duration of a depressive episode; and a history of medication treatment resis­tance (Dombrovski et al. 2005; Feske et al. 2004; Gálvez et al. 2013; Haq et al. 2015; Heijnen et al. 2010; Medda et al. 2014a; Moss and Vaidya 2014; Nordenskjöld et al. 2012; Rasmussen 2015).
One important clinical marker is the rate of remission in patients with unipolar depression versus patients with bipolar depression receiving an acute course of ECT. Bipolar depression is an understudied area in mood disorders, which is unfortunate given the relatively poor response to treatment for bipolar depression and the risks for worsening the course of bipolar illness with adjunctive antidepressants (Cheniaux and Nardi 2019). In a meta-analysis of patients receiving ECT who had a diagnosis of either unipolar or bipolar depression, the overall remission rates in both groups were equivalent: 50.9% and 53.2%, respectively (Dierckx et al. 2012). A more recent meta­analysis found similar results, with remission rates of 52.3% in both unipolar and bi­polar depression, although a statistically higher rate of response and speed of response were found in the patients with bipolar depression (Bahji et al. 2019). Manic symp toms during a depressive episode (as measured by the Young Mania Rating Scale) in patients with unipolar or bipolar depression have been shown to have a decreased re­sponse to ECT (Perugi et al. 2012).
-
-
-
-
-
-
-
300 The APA Publishing Textbook of Mood Disorders, Second Edition
https://t.me/med1917
Biological Markers of Response
Biological markers, including genetic and physiological assessments, are potentially important in determining an individual’s response to ECT. Researchers have cor related baseline neuroimaging findings, including decreased hippocampal volume, increased amygdala volume, and connectivity between prefrontal and default mode networks, with a positive response to ECT. Negative predictors of response include deep white matter hyperintensities and medial temporal atrophy (Levy et al. 2019; van Waarde et al. 2015). Machine learning models have also been used to determine neuroimaging biomarkers for response and have found a positive association be tween pretreatment subgenual cingulate volume and ECT response (Redlich et al.
2016). Yao et al. (2019) recently reviewed laboratory and physiological markers associ-
ated with response to ECT. As they pointed out, much of the data are preclinical data in laboratory animals. The human data are preliminary, but some evidence has shown that polymorphisms of the glutamate receptor ionotropic kainate–4 gene (GRIK4) may predict response/nonresponse to ECT (Minelli et al. 2016). There is also prelim­inary evidence that genes involved in dopamine metabolism (catechol-O-methyl- transferase [COMT]) and neurotransmitters associated with depression (tryptophan hydrolase, serotonin and norepinephrine transporters) are associated with response to ECT in depressed patients (Benson-Martin et al. 2016). Yao et al. (2019) also de­scribed very preliminary data in a small study (N=11) that associated the methylation rate of the brain-derived neurotrophic factor gene (BDNF) with remission in ECT (Kleimann et al. 2015).
Electroencephalographic and polysomnographic results and abnormalities in the
hypothalamic-pituitary-adrenal (HPA) axis are also physiological markers of re sponse to ECT (Yao et al. 2019). Most of these findings suffer from problems with specificity and sensitivity that make them difficult to use in prescribing ECT clinically, but they do provide insights into the mechanisms by which ECT exerts its therapeutic effect. The first electroencephalographic findings were from Max Fink (1979), who demonstrated that delta-wave or slow electroencephalographic rhythms during the ECT-induced seizure were necessary for clinical improvement. More recent findings support the use of electroencephalography in predicting response to ECT. Twenty one-channel resting electroencephalography findings showed greater baseline ante­rior delta coherence (hypothesized to show intact neural circuitry, which could allow for better seizure propagation) (Scangos et al. 2019), ictal spectral amplitude and co­herence, shorter latency until slow-wave onset (Krystal et al. 1995), and postictal elec­troencephalographic seizure suppression (Jagadisha et al. 2003; Scangos et al. 2019). However, some studies have found that electroencephalographic seizure expression is not related to ECT response (Nobler et al. 2000). Another line of reasoning is that the postictal response (e.g., reduced blood flow in the frontal regions and increased postictal slow-wave activities) is correlated with clinical response. These researchers hypothesize that the response to ECT is linked to activation of inhibitory GABA mechanisms (Sackeim 1994).
Sleep parameters have also been investigated as predictors of response. ECT is as-
sociated with an increase in the quality of sleep indices. Patients who achieved stable remission over time demonstrated significant increases in slow-wave sleep and rapid
-
-
-
-
301 Electroconvulsive Therapy
https://t.me/med1917
eye movement (REM) sleep duration and significant decreases in REM density com­pared with patients who did not experience symptom remission (Göder et al. 2016). In this same study, a higher density of the first REM sleep period was significantly as sociated with better ECT outcome. Grunhaus et al. (1994) found that patients who had a significantly shorter REM latency after a successful course of ECT were more likely to relapse in the 6 months following treatment.
The HPA axis is often investigated using the dexamethasone suppression test, and nonsuppression of cortisol by dexamethasone is evidence of the overactivity of the HPA axis in depression (Carroll 1982; Keller et al. 2017). Higher pretreatment levels of post-dexamethasone cortisol have been correlated with a positive response to ECT (Vukadin et al. 2011; Watts and Groft 2010). A small study found that five of six pa tients who went from nonsuppressors to suppressors of cortisol had a positive re­sponse to ECT, and the one patient who did not convert was a nonresponder (Albala et al. 1981). However, in a study of 42 patients, dexamethasone suppression test results did not predict who would remain in remission at 6-month follow-up, and, in fact, pa tients who had converted from nonsuppressors to suppressors were less likely to maintain remission at 6 months (Coryell and Zimmerman 1983).
Another potential marker is inflammation at baseline, including elevated levels of interleukin-6 (IL-6) (Kruse et al. 2018) and C-reactive protein (CRP) (Carlier et al.
2019), which have also been associated with a positive response to antidepressant medications. In one study, higher levels of IL-6 at baseline, and not other markers of inflammation (e.g., CRP), were found in women who responded to ECT (Kruse et al.
2018). Decreasing levels of IL-6 during treatment were associated with a positive ECT response (Järventausta et al. 2017). A review of inflammatory markers and ECT re sponse found that ECT treatments were associated with an inflammatory response af­ter a session and that the treatments could produce a longer-term reduction in cortisol levels, tumor necrosis factor α, and IL-6 (Yrondi et al. 2018).
-
-
-
-
ECT in Special Populations
ECT has been shown to be safe and effective during pregnancy for comorbid mood disorders (Ward et al. 2018). In this review, there was no evidence that ECT increased the risk of premature contractions, preterm labor, miscarriages, or congenital abnor­malities (Ward et al. 2018). Another review of nine publications on ECT in pregnancy reported complications, including fetal arrhythmia, fetal bradycardia, premature birth, developmental delay, abdominal pain, uterine contraction, vaginal bleeding, placental abruption, and threatened abortion (Coshal et al. 2019); however, the au­thors concluded that, overall, ECT was relatively safe in pregnancy. These reviews and others (Anderson and Reti 2009; Calaway et al. 2016; Pompili et al. 2014; Saatcio­glu and Tomruk 2011; Spodniaková et al. 2015) outline the importance of weighing the risks to the mother and fetus from a severe affective episode against the risks and efficacy of ECT i n mood disorders. Some researchers have concluded that ECT should be used only as a last resort during pregnancy (Leiknes et al. 2015).
ECT has been shown to be both safe and effective in children and adolescents with
intractable mood disorders (Benson and Seiner 2019; Cohen et al. 1997; Grover et al. 2013; Lima et al. 2013; Puffer et al. 2016; Shoirah and Hamoda 2011; Wachtel et al. 2011; Zhand et al. 2015). A negative predictor of response in adolescent females was